Wednesday, July 8, 2026

Drug profile · INN

amphetamine adipate

amphetamine adipate (DELCOBESE) is a dopamine transporter releasing agent. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 2
News articles 0
Drug details — amphetamine adipate
US status
approved
Class
Route
ORAL
Patents
20
Programs
2
Data quality
0.89

Quick answer

amphetamine adipate (DELCOBESE) is a dopamine transporter releasing agent. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN amphetamine adipate
Brand DELCOBESE
Mechanism Dopamine transporter releasing agent
Target Sodium-dependent dopamine transporter
Route ORAL
Formulation CAPSULE

Mechanism of action

Dopamine transporter releasing agent

Primary target: Sodium-dependent dopamine transporter

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Aleniglipron Phase 2 · Structure Therapeutics · Obese
  2. Dose escalation of SA030 Phase 1 · Suzhou Ribo Life · Obese

Related & competitor drugs

  1. amphetamine aspartate Norepinephrine transporter releasing agent
  2. amphetamine sulfate Norepinephrine transporter releasing agent
  3. armodafinil Dopamine transporter inhibitor
  4. bupropion hydrochloride Dopamine transporter inhibitor
  5. dexmethylphenidate hydrochloride Norepinephrine transporter inhibitor
  6. dextroamphetamine sulfate Norepinephrine transporter releasing agent
  1. US 12084350

    Allotrope of carbon having increased electron delocalization

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11933866

    Magnetic resonance maps for analyzing brain tissue

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11892530

    Magnetic resonance maps for analyzing tissue

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11820833

    Peptides that inhibit binding of EPCR to its ligand to treat inflammation

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11718530

    Allotrope of carbon having increased electron delocalization

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11497793

    Compositions and methods for treating glioblastoma

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11219636

    Compositions and methods for treating cancer

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10809323

    Magnetic resonance maps for analyzing tissue

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10738361

    Methods of predicting clinical course and treating multiple sclerosis

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 10639350

    Methods and pharmaceutical compositions for improving wound healing using CD24

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10508136

    Peptides and compositions for prevention of cell adhesion and methods of using same

    Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10113170

    Preventing and treating inflammatory skin diseases

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10028999

    PAR-1 based therapeutic conjugates and uses thereof

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9777050

    Peptides and compositions for prevention of cell adhesion and methods of using same

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9771567

    Klotho variant polypeptides

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 9758831

    Methods of predicting clinical course and treating multiple sclerosis

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 9737571

    Compositions of aquatic origin for prevention of cell adhesion and methods of using same

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 9732124

    Peptides and compositions for prevention of cell adhesion and methods of using same

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 9481894

    Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 9394569

    Methods and kits for early detection of cancer or predisposition thereto

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is amphetamine adipate?

amphetamine adipate (DELCOBESE) is a dopamine transporter releasing agent. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for amphetamine adipate?

DELCOBESE is a marketed brand name for amphetamine adipate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of amphetamine adipate?

amphetamine adipate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.